New OPEX Facility in Germany Showcases Next Generation Automation Solutions to Benefit Customers Worldwide
9.11.2021 17:30:00 EET | Business Wire | Press release
OPEX Corporation, a global provider of innovative warehouse, document and mail automation solutions, is opening a new facility in Germany where customers and product resellers may learn about, test and interact with OPEX automation technology that improves workflow, accelerates change, and drives efficiencies in infrastructure.
Located in the northern German city of Duisburg, the new facility will offer convenient, in-person access to European and international travel, and will be outfitted with remote capabilities when travel is not possible.
The newly leased facility, which will be fully operational in early 2022, will be the only European hub for demonstrating the full range of OPEX solutions to both direct customers and OPEX’s extensive network of product resellers. Currently, the only other facility of its kind is OPEX’s world headquarters in New Jersey.
“Most of our solutions are built to order, so it is important that customers be able to learn about and interact with the technology to better understand how it benefits their business,” said Shaun Lee, OPEX Director of Operations for Europe, Middle East and Africa (EMEA). “We work with clients to simulate the customer’s actual environment and needs to provide an in-depth, end-to-end demonstration of our solutions in action.”
Other features of the new German facility include:
- Training classes to help customers, resellers and OPEX employees learn warehouse, document and mail automation capabilities and skills requirements;
- A space in Europe for product trouble-shooting and repairs of damaged equipment. Formerly, such products had to be sent to the US;
- Warehousing and management of machines and parts to enhance supply chain and delivery times; and
- Access to OPEX’s European technical support staff.
“We have been expanding our facilities, personnel and infrastructure to meet the growing automation needs of our customers in Europe and around the world,” said Scott Maurer, OPEX President, International. “This new operation in Germany will give our customers the automation assistance they require in a location that is ideally located to maximize efficiency.”
OPEX automated warehouse management systems help customers maximize their warehouse space and manage peaks and demands without relying on additional labor. Scalable robots and automated warehouse systems optimize e-commerce fulfillment, micro-fulfillment and reverse logistics to handle returns with speed and reduced labor.
In addition, OPEX’s document and mail automation solutions offer seamless and secure mail sorting, document imaging and payment processing to improve business workflow and throughput while reducing or eliminating intensive document preparation.
About
OPEX Corporation provides Next Generation Automation, including warehouse, document and mail automation solutions, to customers around the globe. With headquarters in Moorestown, NJ―and facilities in Pennsauken, NJ; Plano, TX (Dallas metro); France; Germany; Switzerland; and the United Kingdom―OPEX has more than 1,450 employees committed to reimagining and delivering innovative, scalable, unique technology solutions to solve the business challenges of today.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005371/en/
Contact information
Colleen Ciak
CCiak@opex.com
856.727.1100, ext. 5350
856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom